- Home
- MSW vs ALXO Comparison
MSW vs ALXO Comparison
Compare MSW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSW
- ALXO
- Stock Information
- Founded
- MSW 2012
- ALXO 2015
- Country
- MSW Hong Kong
- ALXO United States
- Employees
- MSW N/A
- ALXO N/A
- Industry
- MSW
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MSW
- ALXO Health Care
- Exchange
- MSW NYSE
- ALXO Nasdaq
- Market Cap
- MSW N/A
- ALXO 76.5M
- IPO Year
- MSW 2024
- ALXO 2020
- Fundamental
- Price
- MSW $3.59
- ALXO $0.62
- Analyst Decision
- MSW
- ALXO Strong Buy
- Analyst Count
- MSW 0
- ALXO 6
- Target Price
- MSW N/A
- ALXO $4.14
- AVG Volume (30 Days)
- MSW 64.5K
- ALXO 1.4M
- Earning Date
- MSW 05-25-2025
- ALXO 03-06-2025
- Dividend Yield
- MSW N/A
- ALXO N/A
- EPS Growth
- MSW 18.78
- ALXO N/A
- EPS
- MSW 0.20
- ALXO N/A
- Revenue
- MSW $31,769,612.00
- ALXO N/A
- Revenue This Year
- MSW N/A
- ALXO N/A
- Revenue Next Year
- MSW N/A
- ALXO N/A
- P/E Ratio
- MSW $17.66
- ALXO N/A
- Revenue Growth
- MSW 30.91
- ALXO N/A
- 52 Week Low
- MSW $2.12
- ALXO $0.59
- 52 Week High
- MSW $10.58
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- MSW N/A
- ALXO 31.52
- Support Level
- MSW N/A
- ALXO $0.65
- Resistance Level
- MSW N/A
- ALXO $0.72
- Average True Range (ATR)
- MSW 0.00
- ALXO 0.07
- MACD
- MSW 0.00
- ALXO -0.00
- Stochastic Oscillator
- MSW 0.00
- ALXO 6.09
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.